AU2017367277B2 - Muscle performance improvement compounds - Google Patents

Muscle performance improvement compounds Download PDF

Info

Publication number
AU2017367277B2
AU2017367277B2 AU2017367277A AU2017367277A AU2017367277B2 AU 2017367277 B2 AU2017367277 B2 AU 2017367277B2 AU 2017367277 A AU2017367277 A AU 2017367277A AU 2017367277 A AU2017367277 A AU 2017367277A AU 2017367277 B2 AU2017367277 B2 AU 2017367277B2
Authority
AU
Australia
Prior art keywords
leu
val
ser
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017367277A
Other languages
English (en)
Other versions
AU2017367277A1 (en
Inventor
Marina Maria Boido
Olena BUTENKO
Roberta SCHELLINO
Jan Willem Vrijbloed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmafox Therapeutics AG
Original Assignee
Pharmafox Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmafox Therapeutics AG filed Critical Pharmafox Therapeutics AG
Publication of AU2017367277A1 publication Critical patent/AU2017367277A1/en
Application granted granted Critical
Publication of AU2017367277B2 publication Critical patent/AU2017367277B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017367277A 2016-11-29 2017-11-28 Muscle performance improvement compounds Active AU2017367277B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1620119.6 2016-11-29
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds
PCT/IB2017/057436 WO2018100483A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Publications (2)

Publication Number Publication Date
AU2017367277A1 AU2017367277A1 (en) 2019-07-04
AU2017367277B2 true AU2017367277B2 (en) 2021-04-01

Family

ID=58073474

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017367277A Active AU2017367277B2 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Country Status (11)

Country Link
US (1) US11407799B2 (cg-RX-API-DMAC7.html)
EP (1) EP3548509A1 (cg-RX-API-DMAC7.html)
JP (2) JP7683901B2 (cg-RX-API-DMAC7.html)
KR (1) KR102622245B1 (cg-RX-API-DMAC7.html)
CN (1) CN110036024B (cg-RX-API-DMAC7.html)
AU (1) AU2017367277B2 (cg-RX-API-DMAC7.html)
CA (1) CA3045245A1 (cg-RX-API-DMAC7.html)
GB (1) GB201620119D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ754625A (cg-RX-API-DMAC7.html)
WO (1) WO2018100483A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903261B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013785B2 (en) 2016-11-10 2021-05-25 Keros Therapeutics, Inc. Activin receptor type IIA variants and methods of use thereof
KR20200085832A (ko) 2017-11-09 2020-07-15 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
CN120535607A (zh) 2018-01-12 2025-08-26 科乐斯疗法公司 激活素受体iib型变体及其使用方法
AU2019266314B2 (en) 2018-05-09 2025-05-15 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP2023512423A (ja) * 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
EP4121090A4 (en) * 2020-03-20 2024-09-04 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
EP4121088A4 (en) * 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4185316A4 (en) * 2020-07-24 2024-07-17 Agency for Science, Technology and Research WOUND HEALING COMPOSITION AND USES THEREOF
BR112023018283A2 (pt) * 2021-03-10 2023-10-31 Acceleron Pharma Inc Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca
KR20230169123A (ko) * 2021-03-10 2023-12-15 악셀레론 파마 인코포레이티드 Actrii-alk4 길항제 및 심부전을 치료하는 방법
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
US20110135638A1 (en) * 2009-11-17 2011-06-09 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503673A (ja) * 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP2056850A4 (en) 2006-08-08 2011-10-12 Univ Louisiana State THERAPEUTIC PROCEDURES FOR NEUROPATHIC PAIN
BRPI0716249A2 (pt) * 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
HUE035240T2 (hu) * 2009-04-27 2018-05-02 Novartis Ag Készítmények és eljárások az izomerõ növelésére
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
US20110135638A1 (en) * 2009-11-17 2011-06-09 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cohen, S. et el.; "Muscle wasting in disease: molecular mechanisms and promising therapies"; Nat. Rev. Drug Discov., 14, 58-74 (2015). doi:10.1038/nrd4467. *
Curcio, F. et al.; "Biomarkers in sarcopenia: A multifactorial approach"; Exp. Gerontol., 85, 1-8 (2016). doi:10.1016/J.EXGER.2016.09.007 *

Also Published As

Publication number Publication date
KR20190085132A (ko) 2019-07-17
CN110036024A (zh) 2019-07-19
JP2023116479A (ja) 2023-08-22
US11407799B2 (en) 2022-08-09
WO2018100483A1 (en) 2018-06-07
JP7683901B2 (ja) 2025-05-27
CN110036024B (zh) 2024-05-07
AU2017367277A1 (en) 2019-07-04
EP3548509A1 (en) 2019-10-09
KR102622245B1 (ko) 2024-01-05
ZA201903261B (en) 2020-02-26
CA3045245A1 (en) 2018-06-07
US20210253654A1 (en) 2021-08-19
NZ754625A (en) 2023-03-31
GB201620119D0 (en) 2017-01-11
JP2019536818A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
AU2017367277B2 (en) Muscle performance improvement compounds
CN111727203B (zh) Wnt替代分子和其用途
JP4790624B2 (ja) 生体分子パーティションモチーフ及びそれらの使用
KR102253597B1 (ko) 듀켄씨 근이영양증의 치료에서의 폴리스타틴
JP2021527656A (ja) プログラニュリンを含む融合タンパク質
CA3049023A1 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
AU2015205918A1 (en) Methods for increasing thermogenic adipocytes
JP2003530875A (ja) Ｇタンパク質共役型受容体（ｇｐｃｒ）のアゴニストおよびアンタゴニスト、および、それらを用いてｇｐｃｒを活性化および阻害する方法
BR122020010972B1 (pt) polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero
TW202140531A (zh) 包含ActRIIa-Fc融合蛋白的醫藥組合物；ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途；ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
CA3066251A1 (en) Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
CN102548617A (zh) Bmp-alk3拮抗剂和促进骨生长的用途
CN119241685A (zh) 激活素受体iia型变体及其使用方法
JP2021502378A (ja) アクチビンＩＩａ型受容体変異体およびそれらの使用方法
US12384822B2 (en) TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity
JP2017513921A (ja) ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質
JP2014502965A (ja) ｕＰＡＲアンタゴニストおよびその使用
CA3062194A1 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7315637B2 (ja) 組換えｒｏｂｏ２タンパク質、組成物、方法およびそれらの使用
PL210720B1 (pl) Chimeryczne lub humanizowane przeciwciało monoklonalne lub jego fragmenty F(ab')2 lub Fab, przeciwciało jednołańcuchowe lub przeciwciało pojedynczej domeny zdolne do wiązania się z ludzkim polipeptydem NogoA_632-640, polinukleotyd, wektor ekspresyjny, układ ekspresyjny, izolowana komórka gospodarza, zastosowanie przeciwciała i kompozycja farmaceutyczna
ES2259458T3 (es) Persefina humana.
CN101627053A (zh) 泛细胞表面受体特异的治疗剂
RU2846293C1 (ru) АНТИТЕЛО К EphA4
KR20230123923A (ko) 항-EphA4 항체
HK40015854B (zh) 激活素受体iia型变体及其使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)